Valneva SE (AYJ.DE)

XETRA - XETRA Delayed Price. Currency in EUR

1.8490

-0.0200

(-1.07%)

At close: 05:35PM CET

Loading interactive chart...

Zacks
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock
The FDA application complements recent label extension submissions to the EMA and Health Canada, highlighting Valneva's strategic push to enhance IXCHIQ's global reach.
GlobeNewswire
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA
To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), November 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the U.S. Food and Drug Administration (FDA) to potentially extend the use of its chikungunya vaccine IXCHIQ®, which is currently approved in adults, to adolescents aged 12 to 17 years. The application also includes adding the two-y